# Clinical Validation of a Noninvasive Multi-Omics Method for Multicancer Early Detection in Retrospective and Prospective Cohorts

Source: https://onco.cc/key-papers/paper-seekincare-j-mol-diagn-2025/  
OnCo record `paper-seekincare-j-mol-diagn-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SeekIn's combined DNA and protein test found six in ten cancers in a laboratory set and seven in ten in people who had bought it, at specificities of 95 to 98 per cent.

## Summary

Li and colleagues report SeekInCare, which combines copy number, fragment size, end motif and oncogenic virus signals from shallow whole-genome sequencing of cell-free DNA with seven protein tumour markers. In a retrospective set of 617 patients with 27 cancer types and 580 without cancer it reached 60.0% sensitivity at 98.3% specificity (area under the curve 0.899), with 37.7%, 50.4%, 66.7% and 78.1% at stages I to IV. In a prospective cohort of 1,203 people who received it as a laboratory-developed test (median follow-up 753 days) it had 70.0% sensitivity at 95.2% specificity.

## Fields

- Kind: Key paper
- Last checked: 2026-10-29
- Journal: The Journal of Molecular Diagnostics
- Year: 2025
- DOI: 10.1016/j.jmoldx.2025.04.001
- Authors: Li S, Geng S, Chen Y, et al.
- Findings: Retrospective: 60.0% sensitivity at 98.3% specificity; stage I 37.7%.; Prospective (1,203 people): 70.0% sensitivity at 95.2% specificity.
- What it means: One of few multi-cancer tests with a stage I figure above one in three, from a case-control set; the prospective figures rest on few cancers.
- Caveats: The prospective cohort's number of cancers is not given in the abstract.; Authors include SeekIn staff.

## Sources

- Journal of Molecular Diagnostics 2025: https://doi.org/10.1016/j.jmoldx.2025.04.001
- PubMed: https://pubmed.ncbi.nlm.nih.gov/40311780/

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [cfDNA fragmentomics](https://onco.cc/technologies/fragmentomics/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/), [Proteomics & phosphoproteomics](https://onco.cc/technologies/proteomics/)
- drugs: [SeekInCare](https://onco.cc/drugs/seekincare/)
- companies: [SeekIn](https://onco.cc/companies/seekin/)

---
JSON: https://onco.cc/api/v1/entities/paper-seekincare-j-mol-diagn-2025.json